News › GlobeNewswire Inc.

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Dec 23, 2025 11:45pm (New York) •By Rosen Law Firm

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following allegations of materially misleading business information. The investigation was triggered by Alvotech's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, following the news. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

← Back to news Read Original Article

Insights

NEM neutral

Gold mining company with low P/E ratio, experiencing price volatility but maintaining strong potential with price target above current trading level

ALVO negative

The company issued materially misleading information regarding its FDA application status. The FDA's complete response letter citing manufacturing deficiencies resulted in a 34% stock price decline, triggering a securities class action investigation for investor losses.

Keywords

#securities fraud #class action lawsuit #FDA rejection #biologics license application #manufacturing deficiencies #investor losses #stock decline

Tickers

ALVO ALVOW

← Prev: Synopsys, Inc. Notice of December 30, 2025 Application Deadline for Class Action Lawsuit- Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Next: ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages SLM Corporation a/k/a Sallie Mae Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLM →